MedTrace Logo

Study of AT-527 in Healthy Subjects (R07496998)

NCT04711187 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2022-02-25

No results posted yet for this study

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects.

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

AT-527 Formulation 1

AT-527 Formulation 1 (R07496998)

OTHER

Placebo Comparator

Placebo Comparator

DRUG

AT-527 Formulation 2

AT-527 Formulation 2 (R07496998)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2021-09-15
Completion
2021-09-15
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711187 on ClinicalTrials.gov